Car T Kymriah denied as not medically necessary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for car t kymriah are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Kymriah on Medical-Necessity Grounds

Kymriah (tisagenlecleucel) is a CAR-T cell therapy — a one-time, individualized immunotherapy that requires a highly specialized treatment setting. UnitedHealthcare routinely issues medical-necessity denials for Kymriah because it applies a detailed clinical-criteria checklist before approving this high-cost therapy. Common triggers include incomplete documentation of prior-treatment history, failure to demonstrate that the patient's cancer meets the exact diagnostic and relapse/refractory profile described in UHC's own coverage policy, or absence of a treating-facility attestation confirming the site is certified to administer CAR-T therapy.

## Why This Denial Is Appealable

Kymriah holds full FDA approval for specific hematologic malignancies. A medical-necessity denial does not mean the therapy is inappropriate for your patient — it means the insurer's reviewers need more evidence. Because insurers must follow their published medical policies, a well-documented appeal that maps clinical facts to each policy criterion has strong footing.

## Federal Appeal Framework

• Internal appeal (Level 1): Submit within the timeframe stated on your Explanation of Benefits. UHC must respond within the federally mandated window (shorter for urgent/expedited requests).
• Expedited review: Available when the standard timeline could seriously jeopardize the patient's health. Request this explicitly and in writing.
• External Independent Review (ACA §2719): After exhausting internal appeals (or after 72 hours without resolution on an expedited request), you may demand external review by an Independent Review Organization (IRO). The insurer is bound by the IRO decision.
• ERISA §503: For employer-sponsored plans, the plan must provide a full-and-fair review. You generally have up to approximately four months from the denial date to initiate external review.

## Documentation to Gather

1. Diagnosis confirmation — pathology reports, flow cytometry, cytogenetics, or molecular testing confirming the exact diagnosis and disease stage. 2. Prior-treatment history — records with start/stop dates and documented outcomes (response, relapse, toxicity) for every prior line of therapy. 3. Clinical severity — current performance-status assessments, disease-burden measurements from imaging or labs, and most recent bone-marrow or staging results. 4. Prescriber medical-necessity letter — a detailed letter from the treating hematologist/oncologist explaining why Kymriah is medically necessary for this patient, referencing the applicable guidelines from the relevant professional society (e.g., the applicable NCCN guideline). 5. Facility certification — documentation that the treatment center is authorized to administer CAR-T therapy and manage cytokine-release syndrome.

## Criteria-Mapping Structure

Obtain a copy of UHC's current published coverage policy for tisagenlecleucel. Then build a side-by-side table: in the left column list each numbered criterion from the policy (and from the FDA-approved prescribing label); in the right column cite the exact chart fact — date, test result, or clinical note — that satisfies it. If a criterion references a guideline organization (such as NCCN), pull the current edition of that guideline and confirm your patient's situation aligns. Submit this table with your appeal letter so the reviewer can confirm compliance criterion by criterion without searching the record.